In 2014, a team of researchers led by SM Jin published the results of a study that aimed to determined if low doses of pioglitazone (Actos) also raised the risk for bladder cancer among diabetic patients.  It has already been demonstrated by many other studies that long-term and high-dose Actos therapy dramatically raises the risk for bladder cancer.

This study, titled “Risk of Bladder Cancer among Patients with Diabetes Treated with a 15 mg Pioglitazone Dose in Korea: A Multi-Center Retrospective Cohort Study.” appeared in the February, 2014 edition of Journal of Korean Medical Science and included a total of “101,953 control patients and 11,240 pioglitazone-treated patients”.

Among the control patients, there were 237 cases of bladder cancer identified, and among Actos patients, there were 30 cases of bladder cancer identified.  Using statistics, the team found that these Actos patients who, we should be sure to note, were using only 15mg/day of the drug, were about 14% more likely to develop bladder cancer than patients who had never used the drug.

Due to the fact that the manufacturer of Actos has failed time and again to warn users of the increased risk for bladder cancer associated with their product, a number of Actos bladder cancer lawsuits have been filed.  If you or a loved one used Actos and suffered bladder cancer, you too may be entitled to significant financial compensation for your injury.

For a free, no-obligation case consultation, contact our team of Actos bladder cancer lawyers at the information provided below.  We have the experience, resources, and skills required to win the compensation you deserve.  Call today and see how we can help.

(855) 452 – 5529